Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | BEACON trial results: safety & efficacy of bitopertin in adults with EPP

William Savage, MD, PhD, Disc Medicine, Watertown, MA, shares the results of the Phase II BEACON trial (ACTRN12622000799752) evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of bitopertin treatment in adults with erythropoietic protoporphyria (EPP). The trial reported a significant reduction in protoporphyrin IX as well as significant improvements in measures of light tolerance. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Employee and stakeholder of Disc Medicine